Clinical Trials on EGFR/HER2 Exon 20 Insertion Mutation

Total 35 results

ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
Blueprint Medicines Corporation

Active, not recruiting

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Metastatic Lung Cancer | Antineoplastic Agents | Brain Metastases | Lung Neoplasm Malignant | EGFR... and other conditions

United States, Canada, Korea, Republic of, Japan, Taiwan
Puma Biotechnology, Inc.

Terminated

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations (SUMMIT)

Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

France, United States, Spain, Belgium, United Kingdom, Serbia, Australia, Israel, Canada, Denmark, Ireland, Italy, Korea, Republic of
Scorpion Therapeutics, Inc.

Recruiting

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Non-Small Cell Lung Cancer | NSCLC | EGFR/HER2 Exon 20 Insertion Mutation

United States, Taiwan
Rain Oncology Inc

Terminated

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN)

NSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB Fusion

United States, Canada, Hong Kong
Groupe Français de Pneumo-Cancérologie

Recruiting

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion (RESAMEX)

Non-small Cell Lung Cancer | EGFR Exon 20 Insertion Mutation

France
Centro de Tratamiento e Investigación sobre Cáncer...

Not yet recruiting

Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO) (CULTRO)

Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Exon 19 Deletion | EGFR G719X | EGFR Exon 21 Mutation

Colombia
Juan LI, MD

Recruiting

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Non Small Cell Lung Cancer | EGFR Exon 20 Insertion Mutation

China
AZ-VUB

Unknown

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

Belgium
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy (PYRAMID-1)

Non-squamous NSCLC | HER2 Exon 20 Mutation

Korea, Republic of, United States, Taiwan, Belgium, Spain, China, Australia, Turkey, Italy, France, Germany, Poland, Russian Federation
Taiho Oncology, Inc.

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2)

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

United States, Japan, Spain, France, Australia, Italy, Korea, Republic of, United Kingdom, Canada, Germany, Turkey, Hong Kong
Blueprint Medicines Corporation

Active, not recruiting

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditions

United States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
Guangdong Provincial People's Hospital
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Non-Small Cell Lung Cancer | BRAF V600 Mutation | MET Amplification | MET Exon 14 Skipping Mutation | RET Driver Mutation | Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation

China
Cullinan Therapeutics Inc.

Recruiting

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1)

Non Small Cell Lung Cancer | EGFR Exon 20 Mutation

United States, Taiwan, Spain, Korea, Republic of, Japan, Singapore, Italy, Netherlands, Hong Kong
Blueprint Medicines Corporation

Terminated

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Neoplasms | Respiratory Tract Diseases | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | Non Small Cell Lung... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Spectrum Pharmaceuticals, Inc

Active, not recruiting

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

EGFR Exon 20 Mutation | ERBB2 Gene Mutation | Recurrent Lung Non-Small Cell Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7

United States
ArriVent BioPharma, Inc.
Allist Pharmaceuticals, Inc.

Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 Mutations

United States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom
National Cancer Centre, Singapore

Recruiting

A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC

Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer

Korea, Republic of, Taiwan, Singapore
Taiho Oncology, Inc.

Recruiting

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (REZILIENT3)

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

United States, Spain, Canada, Italy, Israel, Japan, United Kingdom, Korea, Republic of, Germany, France, Turkey, Belgium, Netherlands, Philippines, Poland, Singapore
Yongchang Zhang

Recruiting

PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC

HER2 Insertion Mutation Positive Advanced NSCLC

China
National Taiwan University Hospital

Completed

Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants

Tumor Progression | EGFR Exon 19 Mutation

Taiwan
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7 | EGFR Exon 19 Deletion Mutation | EGFR NP_005219.2:p.L858R

United States
Bayer

Recruiting

A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United States
Bayer

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

Hong Kong, United States, Taiwan, Spain, Belgium, China, Japan, France, Korea, Republic of, Singapore, Poland, Israel, Italy, Netherlands, Portugal, Brazil
Bayer

Recruiting

A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United States
Bayer

Recruiting

A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United Kingdom
Bayer

Active, not recruiting

A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United States
Bayer

Completed

A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

Netherlands
Peking Union Medical College Hospital

Not yet recruiting

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

Non Small Cell Lung Cancer | Immune Checkpoint Inhibitor | EGFR Exon 21 Mutation

China
Amsterdam UMC, location VUmc

Unknown

Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients

NSCLC | EGFR-mutation | HER2-expression

Netherlands
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
University of Chicago
Novartis

Terminated

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Human Papillomavirus Infection | Recurrent Oropharyngeal Squamous Cell Carcinoma | FGFR Gene Amplification | FGFR1 Gene Amplification | FGFR2 Gene Amplification | FGFR2 Gene Mutation | FGFR3 Gene Mutation | Recurrent Nasopharynx...

United States
Sanford Health
National Ataxia Foundation; Beyond Batten Disease Foundation; Pitt Hopkins Research... and other collaborators

Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (CoRDS)

Mitochondrial Diseases | Retinitis Pigmentosa | Myasthenia Gravis | Eosinophilic Gastroenteritis | Multiple System Atrophy | Leiomyosarcoma | Leukodystrophy | Anal Fistula | Spinocerebellar Ataxia Type 3 | Friedreich Ataxia | Kennedy Disease | Lyme Disease | Hemophagocytic Lymphohistiocytosis | Spinocerebellar Ataxia... and other conditions

United States, Australia

Clinical Trials on EGFR/HER2 Exon 20 Insertion Mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations